Search Within

Deepika Cattry

Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (8)
  2. Department of Medicine (8)
  3. Hematologic Malignancies Research (8)
  4. Hematologic Malignancies, Division of (8)
  5. Myeloma (8)
  6. Genitourinary Oncology Service (2)

More Groups

People
  1. Alexander Lesokhin (8)
  2. Carl Landgren (2)
  3. Hani Hassoun (2)
  4. Nikoletta Lendvai (2)
  5. Samuel Funt (2)
  6. David Page (1)

More People

Years
  1. 2018 (1)
  2. 2016 (1)
  3. 2015 (3)
  4. 2014 (2)
  5. 2013 (1)
Publications
  1. Blood (3)
  2. Journal of Clinical Oncology (2)
  3. Haematologica (1)
  4. Leukemia and Lymphoma (1)
  5. New England Journal of Medicine (1)
Publishers
  1. American Society of Hematology (3)
  2. American Society of Clinical Oncology (2)
  3. Ferrata Storti Foundation (1)
  4. Massachusetts Medical Society (1)
  5. Taylor & Francis Group (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
    Journal Article

    Pianko, M. J.; Funt, S. A.; Page, D. B.; Cattry, D.; Scott, E. C.; Ansell, S. M.; Borrello, I. M.; Gutierrez, M.; Lendvai, N.; Hassoun, H.; more...
    Leukemia and Lymphoma (2018)

    Fulltext@MSK | Save
  • Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study
    Journal Article

    Lesokhin, A. M.; Ansell, S. M.; Armand, P.; Scott, E. C.; Halwani, A.; Gutierrez, M.; Millenson, M. M.; Cohen, A. D.; Schuster, S. J.; Lebovic, D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • The long PD-1 receptor binding kinetics of nivolumab may increase efficacy of subsequent therapy in relapsed and refractory multiple myeloma patients
    Meeting Abstract

    Funt, S. A.; Page, D. B.; Cattry, D.; Lendvai, N.; Hassoun, H.; Landgren, O.; Borrello, I. M.; Lesokhin, A. M.
    Blood (2015)

    Fulltext@MSK | Save
  • Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: Updated safety and efficacy results of a phase 1 study (CA209-039)
    Meeting Abstract

    Armand, P.; Timmerman, J.; Lesokhin, A.; Halwani, A.; Millenson, M.; Schuster, S.; Gutierrez, M.; Scott, E.; Cattry, D.; Freeman, G.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
    Journal Article

    Ansell, S. M.; Lesokhin, A. M.; Borrello, I.; Halwani, A.; Scott, E. C.; Gutierrez, M.; Schuster, S. J.; Millenson, M. M.; Cattry, D.; Freeman, G. J.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save
  • Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies
    Meeting Abstract

    Lesokhin, A. M.; Ansell, S. M.; Armand, P.; Scott, E. C.; Halwani, A.; Gutierrez, M.; Millenson, M. M.; Cohen, A. D.; Schuster, S. J.; Lebovic, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Nivolumab in patients with relapsed or refractory Hodgkin lymphoma - Preliminary safety, efficacy and biomarker results of a phase I study
    Meeting Abstract

    Armand, P.; Ansell, S. M.; Lesokhin, A. M.; Halwani, A.; Millenson, M. M.; Schuster, S. J.; Timmerman, J.; Borrello, I.; Gutierrez, M.; Scott, E. C.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies
    Meeting Abstract

    Lesokhin, A. M.; Gutierrez, M.; Halwani, A. S.; Ansell, S. M.; Armand, P.; Borrello, I.; Segota, Z. E.; Cohen, A. D.; Talpaz, M.; Cattry, D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save